Samsung looks to deepen involvement in biotech/healthcare; Histogenics prices IPO below the range;

@FierceBiotech: Bayer tees up its new #hemophilia drug for an @US_FDA submission. More | Follow @FierceBiotech

@JohnCFierce: Busy biotechs bag $121M in VC cash. Article | Follow @JohnCFierce

@DamianFierce: Considering @GenzymeCorp's party for Cerdelga, how big was the Lemtrada cake? More | Follow @DamianFierce

> Korean conglomerate Samsung, which has invested heavily in biosimilars, says it expects to deepen its involvement in the biotech and healthcare field as it looks to improve revenue. Story

> The regenerative med company Histogenics has priced its IPO at $11, well below the $13 to $15 range it had set for itself. Story

Medical Device News

@FierceMedDev: Edison Nation and Mount Sinai team up for device innovation. More | Follow @FierceMedDev

@EmilyWFierce: Tax-inversion loophole likely to cost the government $2.2B in lost tax revenue next year. Story | Follow @EmilyWFierce

> Illumina and Sequenom lay prenatal diagnostic patent feud to rest. More

> New study supports effectiveness of 3-D breast cancer mammography. News

> Xeltis gets $34M to develop biodegradable heart valves and vessels. Article

Pharma News

@FiercePharma: IMS: Rebates, discounts could take an $80B bite out of U.S. drug spending through 2018. Story | Follow @FiercePharma

@CarlyHFierce: J&J looks for Xarelto boost in real-world cost data. Article | Follow @CarlyHFierce

> Pfizer believes a dose of confidence will help it sell biosimilars. More

> Will buyers go after Mylan once it inverts? Don't count on it, analyst says. Story

Drug Delivery News

> DBV's peanut allergy patch tests well, boosting its market value to almost $1B. Report

> Valerion teams up with Catalent to develop orphan drug delivery tech. News

> Recipharm purchases Flamel facility with delivery partnership. Story

> U.S. Army deploys a novel topical antiseptic to fight ebolavirus. Article

> NIH grants $20M to develop an intravaginal ring to prevent HIV. More

Diagnostics News

> Cepheid wins FDA nod for norovirus test. Report

> Germany's nanoPET partners with Boehringer Ingelheim for imaging Dx deal. News

> Philips gets FDA approval for spectral imaging system. Story

> Roche dives into prenatal Dx space with Ariosa purchase. Item

> U.K. and Wellcome Trust back trial of new, 15-minute Ebola test in West Africa. Article

Pharma Marketing News

> PhIII failure dashes Novartis' hopes of Gilenya label expansion. Report

> Reports: BMS whittles China sales operation by 1,000. More

> J&J looks for Xarelto boost in real-world cost data. Story

> Pfizer believes a dose of confidence will help it sell biosimilars. Link

> IMS: Rebates, discounts could take an $80B bite out of U.S. drug spending through 2018. Article

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.